ResearcherPfizer (United States)No recent work listed

Shu‐Hui Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8580-2843; OpenAlex author ID A5100763278. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2019: 1 paper

Papers 1

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Last author DOI 10.1038/s41598-019-53130-4 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guoyun Zhu · 1 shared paper, 2019 · strength 0.07
- Paper Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic… DOI 10.1038/s41598-019-53130-4 ↗
Xiaohui Liu · 1 shared paper, 2019 · strength 0.07
- Paper Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic… DOI 10.1038/s41598-019-53130-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.